Search results
Results from the WOW.Com Content Network
25C-NBOMe (NBOMe-2C-C, 2C-C-NBOMe, Cimbi-82) is a psychedelic drug and derivative of the psychedelic phenethylamine 2C-C. 25C-NBOMe appeared on online vendor sites in 2010 but was not reported in the literature until 2011. [3]
The 25-NB (25x-NBx) series, or NBOMe series, also known as the N-benzylphenethylamines, is a family of serotonergic psychedelics. [1] [2] They are substituted phenethylamines and were derived from the 2C family. [2] The most commonly encountered NBOMe drugs are 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe. [3]
Download as PDF; Printable version; In other projects Wikimedia Commons; Wikidata item; ... including 25B-NBOMe, 25D-NBOMe, 25E-NBOMe, 25H-NBOMe, and 25N-NBOMe.
In vitro studies, 25C-NBOMe has been shown to exhibit cytotoxicity on neuronal cell lines SH-SY5Y, PC12, and SN471, and the compound was more potent than methamphetamine at reducing the visibility of the respective cells; the neurotoxicity of the compound involves activation of MAPK/ERK cascade and inhibition of Akt/PKB signaling pathway.
On Nov 15, 2013, the DEA added 25I-NBOMe (and 25C-, and 25B-NBOMe) to Schedule I using their emergency scheduling powers, making those NBOMe compounds "temporarily" in Schedule I for 2 years. [46] In November 2015, the temporary scheduling was extended for an additional year [ 77 ] while permanent scheduling was arranged.
(The Center Square) – As the Illinois Environmental Protection Agency announces another round of funding for an electric vehicle rebate program, the landscape is changing after a new ...
25CN-NBOH is notable as one of the most selective agonists of the serotonin 5-HT 2A receptor yet discovered, with an affinity (pK i) of 8.88 at the human serotonin 5-HT 2A receptor, 100-fold selectivity for the serotonin 5-HT 2A receptor over the serotonin 5-HT 2C receptor, and 46-fold selectivity for the serotonin 5-HT 2A receptor over the serotonin 5-HT 2B receptor.
A three-judge panel for the 9th U.S. Circuit Court of Appeals in San Francisco rejected claims of legal errors at their separate trials held in 2022. Holmes, who started Theranos as a college ...